Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

430P - A novel survival predicting model for breast cancer brain metastasis based on multimodal data

Date

14 Sep 2024

Session

Poster session 15

Topics

Tumour Site

Breast Cancer

Presenters

Zisheng Wu

Citation

Annals of Oncology (2024) 35 (suppl_2): S357-S405. 10.1016/annonc/annonc1579

Authors

Z. Wu, J. Zhou, X. Wu, Z. Jiang, T. Wang

Author affiliations

  • Department Of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, 100071 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 430P

Background

The prognosis of patients with breast cancer brain metastasis (BCBM) remains significantly poor. Accurate prediction of the prognosis of BCBM patients is very important for formulating treatment strategies.

Methods

We retrospectively collected clinicopathological data and MR images per patient diagnosed with BCBM at our center from 2001 to 2021, and validated the updated breast graded prognostic assessment (uB-GPA) in our cohort. Then cox regression analysis was used to identify prognostic clinical factors. Preprocessed MR images and prognostic clinical factors were used together to develop an end-to-end deep learning network based on the transformer encoder in the training set. After feature encoding by the encoder, output sequences were passed to a multi-task logistic regression model to obtain the patients' risk scores. The prognostic performance of the model was evaluated in the test set.

Results

A total of 700 patients with BCBM were enrolled, with a median OS of 11 months (95%CI: 9.8-12.2m). The concordance index (C-index) of uB-GPA was 0.563 (0.551-0.575). Nine clinical factors were shown to be associated with poorer prognosis of patients with BCBM: Age greater than 48 years at BC diagnosis (P=0.003), KPS less than 80 at BCBM diagnosis (P=0.001), triple-negative subtype (P<0.001), initial metastasis site other than the brain (P<0.001), number of brain metastases ≥3 (P<0.001), concurrent leptomeningeal metastasis (P=0.008), not receiving radiotherapy after diagnosis (P=0.003), liver metastasis (P=0.006), and lung metastasis (P=0.049). A deep learning model based on both MR images and clinical factors was developed in the training set (n=166), yielded the C-index of 0.664 and areas under the receiver operative characteristic curve of 0.705, 0.723 and 0.790 respectively for predicting 3-m, 6-m and 12-m OS in the test set (n=36). The median OS of patients in high and low-risk group were 5m (95%CI: 4-9m) and 14m (95%CI: 13m-?), respectively.

Conclusions

This study developed a novel tool to predict survival of patients with BCBM and achieve good performance. It helps in identifying patients' risk of death and in formulating personalized management strategies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.